By contrast, in two patients with primary resistance to selpercatinib, pre-treatment plasma sequencing revealed KRAS mutations (G12D and G12V) shedding into circulation at low allele frequencies otherwise not detected by tumor tissue profiling, suggesting inter-tumoral heterogeneity and limitations of bulk tissue sequencing (Fig. 2e). The gene discussed is KRAS; the disease is neoplasm.